Zealand’s Amylin Obesity Drug Could Rival Novo’s - But It Needs A Partner

The Danish company believes amylin analog petrelintide can compete with GLP-1 agonists – and hopes an imminent Phase III readout from Novo Nordisk’s rival drug will give it a boost too.